RxDoctor Payments Data

Byron Holm, MD

Family Medicine · Plymouth, INNPI 1538154018

Payments from drug & device makers

$2,121in general payments, 2019–2025

Across 135 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$476
  • Novo Nordisk$399
  • GSK$191
  • Amgen$184
  • AbbVie$152
  • Dexcom, Inc.$83
  • plus $635 from 17 others

What the payments were for

  • Food & beverage$1,82186%
  • Education$30014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,121 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$72,233
Medicare patients
196
Services billed
1,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban709$164,710
OzempicSemaglutide42$51,668
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$39,161
TradjentaLinagliptin251$37,075
FarxigaDapagliflozin Propanediol143$27,040
Breo ElliptaFluticasone/Vilanterol49$21,551
JardianceEmpagliflozin70$21,106
RybelsusSemaglutide18$18,716
EntrestoSacubitril/Valsartan72$18,652
XareltoRivaroxaban115$18,178
TrulicityDulaglutide25$16,129
LantusInsulin Glargine,hum.Rec.Anlog182$13,292
Incruse ElliptaUmeclidinium Bromide33$12,766
Potassium Chloride909$10,694
Pantoprazole Sodium1,471$9,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$38$172,322733 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$191$80,180154 claims
Novo NordiskOzempic, Rybelsus, Tresiba$399$75,12373 claims
Boehringer IngelheimTradjenta, Jardiance$39$58,181321 claims
AstraZenecaFarxiga$45$27,040143 claims
NovartisEntresto$17$18,65272 claims
Johnson & JohnsonXarelto$68$18,178115 claims
Lilly USA, LLCTrulicity$14$16,12925 claims
Sanofi-aventis U.S. LLCLantus$13$13,292182 claims
Astellas Pharma US IncMyrbetriq$476$6,83841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Plymouth

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →